Sanofi's Kevzara Phase 3 Trial for Covid-19 Failed to Meet Primary Endpoint
01 Setembro 2020 - 2:52AM
Dow Jones News
By Giulia Petroni
Sanofi SA said Tuesday the Phase 3 trial investigating the use
of Kevzara in severely or critically ill Covid-19 patients didn't
meet its primary endpoint and key secondary endpoint.
The 420-patient randomized trial, which was conducted outside
the U.S., was investigating the administration of Kevzara
intravenously at a dose of 200 milligrams or 400 milligrams, the
French pharmaceutical company said.
Sanofi and Regeneron Pharmaceuticals Inc. aren't planning to
conduct further clinical studies for the use of Kevzara in patients
affected by Covid-19, the company said.
Kevzara is a treatment for adults with moderate to severe active
rheumatoid arthritis who haven't responded to or tolerated previous
therapy.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
September 01, 2020 01:37 ET (05:37 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024